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A B S T R A C T   
Serum albumin shows slow clearance from circulation due to neonatal Fc receptor (FcRn)-mediated recycling 
and has been used for half-life extension. We report here fusions to a high-affinity DARPin, binding to Epithelial 
Cell Adhesion Molecule (EpCAM). We developed a novel, efficient expression system for such fusion proteins in 
Pichia pastoris with titers above 300 mg/L of lab-scale shake-flask culture. Since human serum albumin (HSA) 
does not bind to the murine FcRn, half-lives of therapeutic candidates are frequently measured in human FcRn 
transgenic mice, limiting useable tumor models. Additionally, serum albumins with extended half-life have been 
designed. We tested HSA7, motivated by its previously claimed extraordinarily long half-life in mice, which we 
could not confirm. Instead, we determined a half-life of only 29 h for HSA7, comparable to MSA. The fusion of 
HSA7 to a DARPin showed a similar half-life. To rationalize these findings, we measured binding kinetics and 
affinities to murine and human FcRn. Briefly, HSA7 showed affinity to murine FcRn only in the micromolar 
range, comparable to MSA to its cognate murine FcRn, and an affinity in the nanomolar range only to the human 
FcRn. This explains the comparable half-life of MSA and HSA7 in mice, while wild-type-HSA has a half-life of 
only 21 h, as it does not bind the murine FcRn and is not recycled. Thus, HSA-fusions with improved FcRn- 
affinity, such as HSA7, can be used for preclinical experiments in mice when FcRn transgenes cannot be used, 
as they reflect better the complex FcRn-mediated recycling and distribution mechanisms.   
1. Introduction 
Many therapeutic agents such as anti-cancer chemotherapeutics, 
cytokines or antibody fragments are small and thus rapidly cleared from 
the circulation by renal filtration, which hampers their efficacy [1]. To 
maintain long-lasting and efficacious blood levels upon administration, 
but avoid constant infusion or repeated injection, which is often asso-
ciated with toxicity by the initially high peak levels, various half-life 
extension strategies have been explored. Most of those achieve half- 
life extension by simply increasing the size of drugs above the renal 
filtration threshold of 60–70 kDa [1]. A more sophisticated approach for 
half-life extension is to exploit the natural recycling and resorption 
mechanism of the neonatal Fc receptor (FcRn) by coupling, complexa-
tion or genetic fusion to human serum albumin (HSA) [2,3]. We report 
here fusions to a high-affinity targeting protein Designed Ankyrin 
Repeat Protein (DARPin), and the development of a powerful expression 
and purification system for such fusion proteins in Pichia pastoris with 
titers above 300 mg/L in lab-scale shake-flask cultures, making access to 
these fusion proteins very rapid and efficient. 
Serum albumin is the most abundant blood protein and, with a 
concentration of 40 g/L (~600 µM), it constitutes 60% of the total 
plasma protein pool [3]. Nevertheless, two thirds of the serum albumin 
pool are circulating in the non-vascular space [3], e.g., the lymphatic 
system, saliva, the small intestine [4] and the fluid of the respiratory 
* Corresponding authors at: Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland (A. Plückthun), Department 
of Biochemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland and Institute of Pharmacology, University of Bern, Inselspital INO-F, 3010 
Bern, Switzerland (U. Zangemeister-Wittke). 
E-mail addresses: uwe.zangemeister@pki.unibe.ch (U. Zangemeister-Wittke), plueckthun@bioc.uzh.ch (A. Plückthun).  
Contents lists available at ScienceDirect 
European Journal of Pharmaceutics and Biopharmaceutics 
journal homepage: www.elsevier.com/locate/ejpb 
https://doi.org/10.1016/j.ejpb.2021.07.011 
Received 14 May 2021; Received in revised form 14 July 2021; Accepted 19 July 2021   
European Journal of Pharmaceutics and Biopharmaceutics 167 (2021) 104–113
105
tract [5]. The mostly α-helical protein folds into the three homologous 
domains (DI, DII and DIII), and each is divided into an A and B sub-
domain and connected with flexible loops [6]. Its stable structure, high 
solubility, long half-life, biodegradability, and non-toxic and non- 
immunogenic nature, its easy availability, as well as its natural pro-
pensity to bind many different drugs, have motivated its use as carrier in 
drug development. Several HSA-based drugs have been approved for 
clinical use, such as the paclitaxel nanoparticle Abraxane® [3], direct 
HSA-fusion peptides or proteins like GLP-1-HSA [1] and factor IX-HSA 
[2], and more fusion proteins are in late-stage clinical trials. 
Interestingly, serum albumin also seems to actively support drug 
delivery into solid tumors and the tumor microenvironment [7–10]. 
Although the main drivers are still unclear, various receptors including 
albondin (gp60) and secreted protein acidic and rich in cysteine 
(SPARC) are likely involved [3]. Other receptors also contribute to the 
complex transport and distribution of serum albumin. For instance, gp30 
and gp18 are thought to perform a “quality control” and direct damaged 
or heavily modified serum albumin to lysosomal degradation, while 
megalin and cubulin mediate the reabsorption of serum albumin in the 
kidney [3]. 
However, the most prominent and best characterized serum albumin 
receptor is FcRn, which simultaneously also binds and regulates the 
trafficking and half-life of IgGs [2]. For IgGs, it was demonstrated that 
the complex with FcRn is internalized into acidified endosomes in 
endothelial cells by pinocytosis before it recycles back and releases the 
IgG into the blood due to its lower affinity at physiological pH (see 
below). A similar procedure can be expected for HSA. 
HSA in humans has a half-life of 20 d [2]. Although in mice the half- 
life of mouse serum albumin (MSA) is only 30–35 h and thus much 
shorter than HSA in humans [11], it is also regulated by FcRn, since it 
was shown to decrease to about 20 h in mouse strains lacking a func-
tional receptor [11]. Interestingly, this decrease was observed for both 
MSA and IgGs, although the respective native half-lives are largely 
different. In fact, FcRn is not only expressed in endothelial cells, but 
throughout many tissues and cells in the body, including cells of the 
immune system and the blood brain barrier, which contributes to the 
complex and broad biodistribution of serum albumin [2]. 
The FcRn consists of two chains, a 40 kDa α-chain with three 
extracellular domains (α1-α3), a transmembrane domain followed by a 
cytoplasmic tail of 44 amino acids, as well as a 12 kDa, non-covalently 
associated, β-chain (β2m) [2]. Two complex structures for the human 
FcRn (hFcRn), either bound to wild-type (wt) HSA [12] or to a high- 
affinity version of HSA, selected by mutagenesis and yeast display 
(termed HSA13: V418M, T420A, E505G, V547A) [13]), provided 
detailed insight into the molecular mechanism of the HSA-FcRn inter-
action. It is a pH-controlled process, as the protonation of specific his-
tidines at an acidic pH below 6 stabilizes a loop surrounding H166 in the 
α1-domain of FcRn, which carries key residues for the interaction, and 
the protonation of H510 and H535 in HSA results in a conformational 
change in a long loop connecting DIIIA and DIIIB. Subsequently, strong 
hydrophobic interactions of specific tryptophan residues of the FcRn 
with binding pockets in HSA, and a relative orientation shift of the 
subdomains mainly in DIII of HSA characterize the binding [12,13]. 
Schmidt et al. [13] proposed a model in which DIIIB is moving after 
initial binding, allowing full hydrophobic contacts of the W53-pocket. 
Together with the available HSA-FcRn structure, another high-FcRn- 
affinity variant of HSA was reported, namely HSA7 (E505G, V547A), 
which carries only two of the four amino acid substitutions from HSA13 
[13]. While the affinity of HSA13 to the human FcRn was even reported 
as a KD of 8 nM at pH 6, the affinity of HSA7 was 64 nM under the same 
conditions. Importantly, it was claimed that its half-life was increased to 
67.5 h in mice [13], being more than two times longer compared to that 
of MSA and longer than HSA13. These reports had motivated us to 
examine it as a fusion protein for half-life extension. Nonetheless, the 
biochemical rationale still had to be investigated, as the affinity of HSA7 
to the murine FcRn (mFcRn) has not been determined yet. 
A second high-affinity FcRn binder was engineered using knowledge- 
based design, and it was termed HSAK573P [14]. An alignment of all 
known C-terminal amino acid sequences of albumin revealed that only 
human and orangutan serum albumin display a lysine at position 573, 
whereas all other species have a proline there. Consequently, when this 
lysine was mutated to proline, HSAK573P showed strongly increased 
binding to the human FcRn (KD: 61 nM), comparable to that of HSA7. 
However, its affinity to the murine FcRn remained much lower, in the 
range of the MSA binding (KD of 1.6 and 0.8 µM respectively). This 
correlated with its half-life in mice, which was 30 h and, hence, again in 
the range of the MSA half-life [11]. Wt HSA, in contrast, was found to 
essentially not bind the murine FcRn [14–16]. Interestingly, the high 
human FcRn-affinity of the two published HSA variants cannot be easily 
explained from the reported structures [12–14], and there is increasing 
evidence that the murine FcRn binds serum albumins differently 
[13,16]. 
We were interested in investigating half-life extensions with such 
engineered HSA mutants for DARPins. DARPins represent a new class of 
non-IgG binding proteins that can have properties superior to antibodies 
in various biomedical applications, including tumor targeting. They are 
more stable than antibodies, have favorable biophysical properties, 
which increase their freedom of engineering into different formats, and 
they can be readily expressed in E. coli [17]. Nevertheless, due to their 
small size of usually less than 20 kDa, DARPins are rapidly cleared from 
the circulation, resulting in a half-life of only a few minutes [18,19]. We 
previously described the possibility to incorporate a single cysteine and 
a non-natural amino acid into the scaffold for PEGylation [18] or bio-
orthogonal chemical coupling of a half-life extension module like serum 
albumin [19]. In addition, DARPins were fused to unstructured poly-
peptides of different lengths to optimize the half-life of these targeting 
molecules by controlling the apparent molecular weight [20]. 
Here, we investigated the potential of HSA7 for half-life extension of 
fusion proteins, originally motivated by the previous report of an 
extraordinary half-life in FcRn wt mice [13], and re-examined these 
values, determining the role of FcRn binding for the elimination kinetics 
in mice. To correlate these findings with biochemical data, we investi-
gated the affinity of HSA7 for both the human and the murine FcRn 
using detailed SPR analyses. In this comparison, we used wt HSA, which 
does not bind to the murine FcRn, the high-affinity variant HSA7, and 
MSA. 
To study the effect of FcRn binding on serum half-life, human FcRn 
transgenic mice can be used as an alternative [21]. However, this model 
has limitations, too, since the strong overexpression of the hFcRn itself 
leads to altered pharmacokinetic behavior of serum albumins, e.g., un-
naturally long half-lives [13,14], which can result, e.g., in increased 
side-effects for specific drugs in these animals. Additionally, the trans-
genic human FcRn binds MSA still significantly, leading to a competition 
with the HSA-drug fusions [15]. Moreover, some disease models them-
selves require transgenes, and/or cannot be established in these mice. 
To ensure facile production and sufficient material of HSA fusion 
proteins, we used Pichia pastoris [22,23], and developed a highly effi-
cient expression system which allows high cell densities and protein 
titers as well as facile cultivation. Optimizing the P. pastoris strain, in-
duction schemes, carbon source, and construct design, we arrived at a 
method and protocol which now allows to routinely obtain yields of 300 
mg/L in standard laboratory shake flasks. HSA, HSA7 and the fusion 
proteins composed of HSA7 and the DARPin in different configurations 
could be purified from the cell culture supernatant using two consecu-
tive orthogonal affinity chromatography steps. Altogether, this has now 
made the access to these fusion proteins very rapid and efficient. 
Here, we correct the previously reported [13] very long half-life of 
HSA7 in wt mice. Instead, we find that the half-life of HSA7 is compa-
rable to MSA, yet clearly longer than wt HSA. To correlate these findings 
with biochemical analyses, we report here surface plasmon resonance 
(SPR)-data showing that HSA7 binds to the murine FcRn with micro-
molar affinity, which is comparable to the murine FcRn-MSA 
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interaction. In contrast, HSA does not bind to murine FcRn but shows a 
high affinity to the human FcRn. Consequently, micromolar affinity to 
FcRn is the crucial minimal threshold for active in vivo recycling in mice. 
Using a DARPin as an example, our data confirm the tremendous 
potential of the HSA7 expression platform to extend the half-life of small 
proteins in mice as a preferred preclinical model for drug testing. Since 
many favorable effects of serum albumins such as tissue penetration 
depend on an intact FcRn interaction, HSA7 offers the opportunity to 
exploit the FcRn-mediated transport pathways in mice and hence, in 
contrast to wt HSA, more closely mimics the clinical situation with HSA 
in humans. 
2. Materials and methods 
2.1. Cloning of serum albumins and HSA7-DARPin fusions for expression 
For the production in Pichia pastoris, the expression constructs for 
human serum albumin (HSA) and HSA-DARPin fusions (HSA-FLAG, 
HSA7-FLAG, Ec1-HSA7-FLAG or HSA7-Ec1-FLAG) were based on the 
vector pPICZαA (Invitrogen). These configurations were chosen since 
the C-terminal FLAG does not interfere with the transport and leader 
sequences used for P. pastoris expression (see below), and fusing HSA7 to 
the EpCAM-binding DARPin Ec1 either N-terminally or C-terminally 
would allow us to identify the fusion protein with optimal expression 
properties and homogeneity (Fig. 1). The sequences of all constructs are 
shown in Figure S1. To optimize expression of these constructs, we 
investigated different versions of the α-mating factor (αMF) pre-pro 
transport region and the native serum albumin leader sequence. These 
constructs were generated with the same assembly strategy (see below) 
but using different synthetic nucleotide sequences in the assembly PCR 
step. We found that the best yields were obtained by the full-length 
α-mating factor transport region when using a newly developed 
expression protocol optimized for shake-flask scale (described below). 
We thus only list in detail here the optimized construct design 
(Figure S1) and the optimized protocol. 
All optimized constructs contain the methanol-inducible alcohol 
oxidase (AOX1) promotor [24–26] at the 5′-terminus, the αMF sequence 
(including signal sequence, pro-region and the sequence EAEA), which 
is trimmed from the mature protein, followed by the first amino acids of 
HSA (DAHKSE). For the N-terminal DARPin fusion, the EAEA of αMF 
was followed by the amino acids DSGLD. The EpCAM-binding DARPin 
Ec1 [27] and the respective serum albumin (HSA or HSA7) were con-
nected by a (GGS)4GG linker (both when N-terminally or C-terminally 
fused to serum albumin). At the C-terminal end of the ORF is a FLAG tag, 
and at the 3′-terminus of the gene the AOX1 transcription terminator. 
The constructs were generated as described in the following. First, 
vectors containing HSA or HSA7 (containing the mutations E505G and 
V547A [13]) were obtained as a synthetic gene from Life Technologies. 
The vectors contained: a BsaI restriction site, the AOX1 promotor, the 
αMF secretion sequence, the HSA or HSA7 sequence, a FLAG tag and the 
AOX terminator followed by a BglII restriction site. The BsaI or BglII- 
complementary restriction sites BamHI or HindIII on the pPICZαA vec-
tor were used for the insertion of these constructs. 
Second, for the generation of the DARPin fusions, PCR on the ob-
tained vectors containing the synthetic sequences (Life Technologies) 
was performed to generate a first fragment. Either the HSA or HSA7 
sequence followed by a FLAG tag, the AOX terminator and the BglII 
restriction site (N-terminal DARPin fusion), or the BsaI restriction site 
followed by the AOX1 promotor, the αMF secretion signal and the HSA 
or HSA7 (C-terminal DARPin fusion), were amplified. Third, an assem-
bly PCR using short overlapping sequence stretches was performed with 
synthetic nucleotide sequences (Integrated DNA Technologies) con-
taining either the BsaI site, AOX1 promotor, αMF secretion signal and a 
cloning cassette, which is flanked by BamHI and HindIII restriction sites 
followed by an encoded (GGS)4GG linker (N-terminal DARPin fusion), or 
the encoded (GGS)4GG linker followed by the described cloning cassette, 
a FLAG tag, the AOX1 terminator and a BglII restriction site (C-terminal 
DARPin fusion). The generated full-length construct PCR fragments 
were cloned into pPICZαA using again BsaI and BglII and the comple-
mentary restrictions sites BamHI and HindIII on the vector. In a last step, 
the described cloning cassette was exchanged by the DARPin Ec1 [27] 
using the 5′ BamHI and 3′ HindIII restriction sites. 
2.2. Protein expression in Pichia pastoris 
All media were sterile-filtered and methanol was added afterwards. 
Fig. 1. Analysis of purified HSA variants and DARPin fusions after expression in P. pastoris. A) SDS-PAGE gel analysis. B) Analytical gel filtration for apparent 
molecular size and homogeneity analysis; red: sample chromatogram; light grey: protein standard chromatogram. 
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All steps with cells were performed under sterile conditions. The vectors 
containing the αMF-HSA-FLAG, αMF-HSA7-FLAG, αMF-Ec1-HSA7-FLAG 
or αMF-HSA7-Ec1-FLAG construct were linearized using the BglII site (in 
front of the AOX promotor). The linearized plasmid was purified with 
isopropanol precipitation, and electrocompetent SMD1163 (his4 pep4 
prb1, phenotype His–) or KM71H (aox1::ARG4, arg4, phenotype MutS) 
cells (Invitrogen) were transformed with the linearized plasmid. Forty 
microliters of cells were mixed with 400 ng of linearized plasmid DNA 
and the whole mix was plated after electroporation with 1500 V 
(Eppendorf Electroporator 2510) on YPD-Agar (Formedium) plates 
(containing 100 µg/mL Zeocin™) following standard procedures [28]. 
After 3–4 days of incubation at 30◦C, single colonies were re-plated on 
fresh YDP-agar (100 µg/mL Zeocin™). 
A pre-culture of 5 mL YPD medium (Formedium) was inoculated 
from a single colony and incubated for 18 h at 30◦C with continuous 
shaking. Thereafter, 5 mL BMMY medium (1% (w/v) yeast extract, 2% 
(w/v) peptone, 100 mM potassium phosphate pH 6.0, 1.34% (w/v) yeast 
nitrogen base (YNB, w/o amino acids), 0.5% (v/v) methanol, 0.04% (w/ 
v) biotin) were inoculated to an OD600 of 1.0, and the cells were grown 
for 24 h at 30◦C with continuous shaking in the expression medium. 
Finally, the cell suspension was centrifuged for 5 min at 1500 × g, and 
the supernatant was separated from the pellet. 
To monitor expression yields and determine product integrity, the C- 
terminal FLAG-tag was detected by dot blotting. Four microliters of 
supernatant were added to a nitrocellulose membrane (Whatman) and 
the membrane was dried for 10 min at 37◦C. This step was repeated two 
times and the membrane subsequently blocked with PBS-TM-5 (PBS, 
0.05% (v/v) TWEEN®-20, 5% (w/v) non-fat milk powder (AppliChem)), 
incubated with the monoclonal mouse anti-FLAG M2 antibody (Sigma 
Aldrich, F3165) in PBS-TM-2.5 (PBS, 0.05% TWEEN®-20, 2.5% (w/v) 
non-fat milk powder) and washed 4 times with PBS-T (PBS pH 7.4, 
0.05% TWEEN®-20) for 5 min before incubating it with the goat anti- 
mouse IgG-AP conjugate (Sigma Aldrich, A3562) in PBS-TM-2.5 (PBS, 
0.05% TWEEN®-20, 2.5% (w/v) non-fat milk powder) and washing it 
again as before. All blocking and incubation steps were performed for 1 
h at room temperature. 
The membrane was developed using BCIP®-NBT solution (Sigma 
Aldrich) and, when spots became clearly visible, the development was 
stopped with a single wash step with PBS-T for 5 min. For each construct 
in each strain, 10–15 clones were tested, and the supernatant of well- 
performing clones was also analyzed by SDS-PAGE. 
The best-performing clones were used for the inoculation of 5 mL 
YPD medium and grown for 18 h at 30◦C with continuous shaking. After 
centrifugation, the cell pellet was resuspended in 1 mL fresh YPD me-
dium containing 20% (v/v) glycerol, the cells were gradually frozen 
using an isopropanol freezing container (Thermo Fisher Scientific) and 
stored at − 80◦C for conservation. 
For lab-scale expression (0.5 L), previously conserved cells of a 
selected clone were re-streaked on a YPD-Agar plate (containing 100 µg/ 
mL Zeocin™) and after 2–3 days of incubation at 30 ◦C two 100 mL pre- 
cultures in YPD medium in unbaffled 1 L shake flasks were inoculated 
from a single colony and grown under continuous shaking (125 rpm, ø 
25 mm) overnight. The next day, 0.5 L BMMSY expression medium (1% 
(w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium phosphate 
pH 6.0, 1.34% (w/v) YNB (w/o amino acids), 2% (v/v) methanol, 0.04% 
(w/v) biotin), 1% (v/v) sorbitol) in 2.5 L Ultra YieldTM flasks (THOM-
SON instrument company, #931136B) was inoculated to an OD600 of 1.0 
with the pre-cultures. A minimal pre-culture dilution factor of 1:25 was 
used to avoid high glucose concentrations from residual YPD medium in 
the expression culture. Ninety microliters antifoam 204 (Sigma Aldrich) 
were added, the flasks sealed with AirOtopTM lids (THOMSON instru-
ment company, #899425) and the expression culture was incubated at 
30 ◦C for 72 h under continuous shaking (300 rpm, ø 25 mm). Two 
percent (v/v) methanol was added every 24 h. Expression cultures were 
centrifuged at 1500 × g for 10 min and the supernatant harvested and 
sterile filtered (VacuCap® PF bottle-top filter device, PALL) and stored 
at 4 ◦C prior to protein purification. Note that above, the final expression 
protocol is described, whereas throughout optimization different 
methanol feeding concentrations, glycerol instead of sorbitol, and an 
expression without glycerol or sorbitol were all tested. 
2.3. Purification of serum albumins and HSA7-DARPin fusions from the 
supernatant 
All purification steps were performed using an ÄKTA™ Pure chro-
matography system (GE healthcare). The filtered supernatants 
(500–1000 mL) were loaded to a 20 mL glass-shell self-packed AlbuPure 
(Prometic Bioseparations) resin column. Briefly, the column was equil-
ibrated with 5 column volumes (CV) equilibration buffer (50 mM so-
dium citrate, pH 5.5), the supernatant loaded with a minimal contact 
time of 4 min, and the column washed with 5 CV equilibration buffer 
followed by 5 CV wash buffer 1 (50 mM sodium phosphate, pH 6.0) and 
10 CV wash buffer 2 (50 mM sodium citrate). Ten CV elution buffer (50 
mM ammonium acetate, 100 mM sodium octanoate, pH 7.0) were 
applied and protein-containing fractions (280 nm absorbance) collected 
and pooled. All AlbuPure-steps were run with a flow rate of 5 mL/min. 
To remove aggregates, the collected protein pools were loaded to a 
strong anion exchange MonoQ 5/50 GL column (GE healthcare). After 
equilibration with 20 mM HEPES, 20 mM NaCl, pH 8, the protein pool 
was loaded with a contact time of 4 min, the column washed with 10 CV 
equilibration buffer and the protein eluted with a linear gradient of 
10–50% 20 mM HEPES, 1 M NaCl, pH 8 over 50 CV with a contact time 
of 4 min. Protein-containing fractions (280 nm absorption) were 
collected, dialyzed against PBS and pooled. 
2.4. Endotoxin removal 
For endotoxin removal, purified proteins were applied to an Endo-
Trap HD affinity resin according to the manufacturer’s instructions 
(Hyglos, product discontinued, now marketed by Lionex GmbH, 
Braunschweig). Proteins were buffer-exchanged to endotoxin-free Dul-
becco’s PBS (Millipore) using PD-10 desalting columns (GE Healthcare). 
The endotoxin content was determined after 1:40 dilution in glucan 
blocking buffer (Charles River Laboratories, BG120) with an EndoSafe 
Portable Test System (Charles River Laboratories) using PTS test car-
tridges (Charles River Laboratories) with 0.5–0.005 EU/mL sensitivity. 
In all purified samples, the amount of detected endotoxin was always 
below 0.7 EU/ml or 1.3 EU/mg of protein. 
2.5. SDS-PAGE analysis 
Two micrograms of protein were analyzed by SDS-PAGE using 
4–12% ExpressPlusTM PAGE Gels (GenScript) with MOPS SDS running 
buffer (GenScript) according to the manufacturer’s instructions. As 
molecular weight standard PageRuler™ Prestained Protein Ladder 
(Thermo Fisher Scientific) was used. Gels were stained according to the 
manufacturer’s instructions with Coomassie Brilliant Blue R250 (Sigma- 
Aldrich). 
2.6. Analytical gel filtration 
Proteins were analyzed on an Agilent Advanced BioSEC column (300 
Å, 2.7 µm, 4.6 × 300 mm, Agilent) connected to an Agilent 1260 Infinity 
Bio-inert Quaternary LC HPLC system (Agilent). Ten microliters of 
protein dilutions in PBS pH 7.4 were injected into the HPLC system at a 
flow rate of 0.35 mL/min. The elution profiles were monitored by 
absorbance at 280 nm. A molecular weight gel filtration standard 
(Agilent) was included. 
2.7. Binding kinetics by surface plasmon resonance 
The binding kinetics of serum albumins or serum albumin-DARPin 
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fusions to FcRn were determined on a ProteOn™ XPR36 instrument 
(BioRad). Human or murine FcRn fusions with glutathione-S-transferase 
(FcRn-GST) were expressed and purified as previously described 
[29,30]. FcRn-GST was biotinylated using NHS-LC-LC-Biotin (Thermo 
Fisher Scientific) dissolved in DMSO. Briefly, the proteins were incu-
bated with 8 × molar excess of NHS-linker for 2 h on ice and thoroughly 
desalted (ZebaSpin column, Thermo Fisher) using PBS buffer. To assess 
the degree of biotinylation, the desalted proteins were mixed with 
commercially available streptavidin (1.2 g/L in PBS) in 2 × molar 
excess, incubated for 1–2 h at 24 ◦C and analyzed on an SDS-PAGE gel. 
Two ligand channels of a NeutrAvidin-functionalized chip (ProteOn™ 
NLC Sensor Chip, BioRad) were coated with biotinylated FcRn-GST in 
PBS-T (PBS pH 7.4, 0.005% TWEEN®-20) in a high or low density. For 
each ligand/analyte pair, coating densities were optimized, reaching 
minimally 500 RU (low density) and maximally 1200 RU (high density). 
After coating, the running buffer was changed to PBS-T pH 6.0. After 
three buffer injections for baseline stabilization, a 1:1.85 dilution series 
of analyte was injected, starting with optimized concentrations for each 
construct of 1.34 μM (HSA7-Ec1), 13.73 μM (HSA7) or 5.97 μM (MSA) 
on the high- or low-density ligand channels. The flow rate of all steps 
was 60 μL/min, the association time was set to 250 s and the dissociation 
time to 800 s. The chip surface coated with FcRn-GST ligand was re-
generated between analyte runs by a single PBS-T pH 7.4 injection with 
a flow rate of 60 μL/min and a contact time of 200 s. Data and assay 
quality was assured by verifying that buffer injections over coated 
channels or analyte (serum albumin) injections over uncoated channels 
did not show significant binding signals. The sensorgrams of analyte 
injections at a concentration giving a sufficient signal-to-noise ratio, but 
no non-specific chip surface binding, were double-referenced by sub-
traction of inter-spot signals and a blank analyte channel signal. The 
parameters of a 1:1 Langmuir binding model, or in the case of MSA/ 
mFcRn a heterogeneous ligand model, were fit to the data using the 
ProteOn™ Manager Software (Version 3.1.0.6, BioRad). 
2.8. Mice 
Female Crl:CD1-Foxn1nu mice 6–8 weeks of age were purchased from 
Charles River Laboratories and kept under sterile conditions according 
to the guidelines of the veterinary ordinance of the Kanton Zurich for 
animal welfare. 
2.9. Pharmacokinetic analysis – Blood clearance in mice 
To determine the blood clearance kinetics of HSA, HSA7 and the 
HSA7-Ec1 fusion protein, mice were injected intravenously (i.v.) into 
the tail vein with 4 mg/kg of protein (N = 5 mice per group). This 
represents a typical dose for the pharmacokinetic characterization of 
proteins in this half-life range [13,14,20], which results, in a first 
approximation, in serum protein levels that can be well detected by 
ELISA. Only constructs showing high homogeneity were selected for in 
vivo experiments (Fig. 1A, B). Blood samples were drawn from the 
saphenous vein after 3 min, 1, 8, 24, 48, 72 and 96 h. After blood 
coagulation at room temperature for 30 min, serum was prepared by two 
centrifugation steps (coagulated blood 7 min at 3100 × g, serum 3 min 
5000 × g, room temperature) and stored at − 80 ◦C until quantification 
of serum concentrations by a carefully calibrated pull-down sandwich 
ELISA. 
Black 384-well Immuno Plates (Thermo Fischer Scientific) were 
coated with 20 μL mouse anti-FLAG-M2 antibody (Sigma Aldrich, 
F3165) at a dilution of 1:500 in PBS pH 7.4 at 4◦C overnight. The wells 
were blocked for 1 h at room temperature with 70 μL PBS-TM-4 (PBS pH 
7.4, 0.05% TWEEN®-20, 4% w/v nonfat dried milk powder (Appli-
Chem)). The wells were washed three times with 100 µL PBS-T (PBS pH 
7.4, 0.05% TWEEN®-20) at room temperature using a plate-washing 
device (BioTEK Instruments). For the quantification of serum concen-
trations, a serial dilution of purified serum albumins or serum albumin- 
DARPin fusion in PBS-TM-4 was prepared, ranging from 125 to 0.12 nM. 
The PBS-TM-4 was supplemented with serum from an untreated animal 
in a 1:50 dilution to ensure an identical composition of the sample 
matrix. Twenty microliters of the diluted serum samples (1:50 in PBS- 
TM-4) or the standard dilution series were applied to the previously 
coated and blocked wells. Control wells were incubated with PBS-TM-4 
without serum albumin or mouse serum for background subtraction. 
Furthermore, for assay quality assessment, the highest standard curve 
concentration of the purified protein without mouse serum, wells 
without solution, and wells with PBS-TM-4 without any protein or 
coating, were measured on the same plate. The plate was incubated for 
1 h at room temperature, washed three times with PBS-T as above and 
incubated for 1 h at room temperature with 20 µL of a 1:4000 dilution of 
a mouse monoclonal anti-human serum albumin HRP antibody (AbCam, 
ab24458) in PBS-TM-4. After four final washing steps with PBS-T as 
above, the assay was developed using Amplex UltraRed (Thermo Fisher 
Scientific). A 10 mM Amplex UltraRed solution in DMSO was diluted 
1:400 in 75 mM Na-citrate pH 6.0, 0.0035% (w/w) H2O2 and 20 µL were 
added to each well for detection. Fluorescence was measured every 
three minutes using a BioTek Synergy HT plate reader (BioTek In-
struments). Following each solution addition to the wells in the protocol, 
plates were centrifuged for 1 min at 1500 × g and all incubation steps 
were conducted in a temperature-controlled environment. 
All standards were prepared in triplicates (N = 3) and each data point 
was measured in quadruplicates (N = 4). The signal over time for the 
assay development of the highest concentration of the standard dilutions 
was plotted, and a read in the linear range of the signal development 
curve was selected (usually 6–12 min after dye addition). Non-linear 
regression using a 4PL-model was used to fit the data from serial stan-
dard dilutions to obtain a standard curve (Graph Pad Prism Version 6.07, 
GraphPad Software Inc.). Protein concentrations in the serum samples 
were quantified by interpolation of measured data points with the 
respective standard curve. 
Data fitting and calculation of pharmacokinetic parameters with a 
two-compartment model (2-phase exponential decay) was performed 
using GraphPad Prism 6 (Version 6.07, GraphPad Software Inc.). The 
area under the curve (AUC) was calculated by integration of the two- 
compartment model curves, describing the distribution and elimina-
tion of the various i.v. injected serum albumins and DARPin-fusions. 
Clearance (CL), elimination rate constant (ke) and apparent volume of 
distribution (Vd) were calculated with the formulas: CL = D/AUC, ke =
ln (2)/ τβ1/2, Vd = CL/ke, where D is the dose and τβ1/2 is the terminal 
half-life. 
3. Results 
3.1. Production of serum albumins and DARPin-fusions in Pichia pastoris 
at high yield and purity 
We developed a method that allowed us to express serum albumins 
and their fusion proteins in P. pastoris with a titer of > 300 mg/L in 
simple shake flasks. We typically used 0.5 L medium in 2.5-L flasks. We 
achieved this high yield by combining four components, (i) the use of the 
strain KM71H, which is not protease-deficient, (ii) an optimized meth-
anol feeding plan and time course, (iii) the non-promotor-inhibiting 
carbon source sorbitol and (iv) shake flasks with a specific baffle design. 
When developing this expression strategy, we measured the meth-
anol content of the expression medium over time with 1D H-NMR 
(methanol peak integration) and found that it was massively consumed 
in the growth phase, because methanol serves as carbon source via the 
alcohol oxidase pathway, in addition to inducing the AOX promotor 
(data not shown). Consequently, a refeeding schedule was designed to 
keep the methanol level constant at 2% (v/v) throughout the growth 
phase. We therefore refute the widespread belief that methanol is toxic 
to P. pastoris [31], since in the saturation phase we measured methanol 
levels of > 5% (v/v), with no signs of toxicity to the cells, which would 
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be manifested, e.g., by a decrease in OD600. We added sorbitol to the 
expression medium at the beginning, as it is a carbon source that does 
not inhibit the AOX promotor. While it neither increased the expression 
yield nor the cell density by itself, it decreased the required expression 
time, compared to an AOX-promoter-inhibiting carbon source like 
glycerol, as methanol can only induce the AOX promotor after the 
inhibiting carbon source is consumed. Therefore, the presence of sor-
bitol resulted in a better protein quality (lower protease-mediated 
degradation in the medium). Without an additional carbon source in 
the expression medium, cell densities and expression yields were 
significantly lower. 
Frequently, the protease-deficient strain SMD1163 is used for 
secreted proteins. However, we found that this designed sorbitol and 
methanol feeding schedule applied to clones of the strain KM71H, which 
is not protease-deficient, greatly increased the protein yields by a factor 
of 5–10, compared to SMD1163. 
Finally, the expression in UltraYield™ flasks enabled a filling volume 
of 0.5 L in a 2.5 L shake flask, while in a conventional 1 L shake flask the 
maximum filling volume can only be 100 mL without decreasing the cell 
growth and protein yield by diminished aeration. 
Using this optimized expression strategy, HSA, HSA7 and the fusion 
proteins composed of HSA7 and the DARPin Ec1 in different configu-
rations were purified from the P. pastoris cell culture supernatant with 
two consecutive orthogonal affinity chromatography steps, using first an 
AlbuPure® and second an anion exchange column, which resulted in 
protein preparations of high purity (Fig. 1A). 
The anion exchange step minimized the aggregate and dimer content 
of all protein pools; however, the N-terminal fusion of the DARPin Ec1 
showed lower homogeneity (Fig. 1B), as detected by analytical gel 
filtration analysis. It was therefore excluded from further 
characterization. 
3.2. HSA7 has very different affinities for the human and the murine 
FcRn 
The purified HSA-constructs and commercially obtained MSA 
(Merck Millipore) were tested by surface plasmon resonance (SPR) at pH 
6.0 to determine the precise affinity parameters for the human and the 
murine FcRn. Both high- and low-density coated ligand channels 
resulted in comparable affinity parameters for each protein, and the fits 
follow well the sensorgram data (Fig. 2). This allows a precise and 
profound characterization of FcRn-binding behavior in a comprehensive 
dataset, consistent with SPR-data representation guidelines, as 
described in [32,33]. All examined analyte/ligand combinations could 
be thoroughly regenerated with a single PBS pH 7.4 injection, showing 
no residual binding at this pH. 
The tested HSA7 showed high-affinity KD values (Table 1) for the 
human FcRn, which compare well with data from the literature [13], 
and it confirms that there is no functional difference between the pro-
teins produced in Pichia pastoris or Saccharomyces cerevisiae. Impor-
tantly, the C-terminal fusion of a DARPin (Ec1) to HSA7 did not mitigate 
the binding to the FcRn (Table 1). 
We measured here for the first time also the affinity of the previously 
reported high-FcRn-affinity HSA variant HSA7 for the murine FcRn and 
found that it was strongly decreased, about 60-fold, compared to the 
human FcRn. As expected, HSA did not bind to the murine FcRn 
(Figure S2). Importantly, the determined affinities for the murine FcRn 
for HSA7 or its C-terminal DARPin fusion are thus in the same single- 
digit micromolar range as for MSA binding to its natural recycling 
receptor. 
MSA binds to the human FcRn with affinities comparable to previ-
ously published data [15], but, interestingly, shows a different binding 
behavior to the human or murine receptor. The interactions with the 
human FcRn correspond to a simple 1:1 binding interaction and could be 
Fig. 2. SPR analysis of the binding kinetics of HSA7, HSA7-Ec1 and MSA to the human and murine FcRn. A 1:1 Langmuir model or heterogeneous ligand model were 
fit to the resulting sensorgrams, and kinetic parameters ka, kd and KD were determined for each interaction. Measured signals are shown in black, fits are shown in 
red. high-dens., high coating density of immobilized biotinylated FcRn-GST, low-dens., low coating density (cf. Section 2.7.). RU, resonance units. 
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well fit with the 1:1 Langmuir model. However, the binding of MSA to 
the murine FcRn follows different, non-1:1 binding kinetics and requires 
a heterogeneous ligand binding model. The applied binding model 
generated a second set of parameters for these interactions, suggesting a 
second type of ligand/analyte interaction at pH 6, at which all the 
measurements were performed. This second interaction has increased 
dissociation rate constants, whereas the association rate constants are 
comparable, also to the human FcRn binding (Table 1). From these re-
sults, we conclude that there is a distinct binding mode of MSA to its 
natural murine FcRn, due to two different conformations at pH 6, which 
allow slow or fast MSA dissociation, possibly by a conformational 
change in the receptor which facilitates dissociation. 
3.3. Binding to the murine FcRn increases the half-life of HSA in mice 
The sandwich ELISA established in this work allows the precise and 
robust measurement of very low HSA concentrations down to 0.2 nM in 
the serum, with an excellent signal-to-noise ratio, and thus it enabled us 
to reliably determine the blood clearance curves of HSA, HSA7 and 
HSA7-Ec1 (Fig. 3). 
As shown in Table 2, analyses of the curves and calculation of the 
underlying pharmacokinetic parameters revealed the fastest clearance 
and elimination rate for HSA in mice, resulting in a half-life of 21 h. For 
HSA7, showing similar micromolar affinity to murine FcRn as MSA, we 
determined a half-life of 29 h. This is substantially shorter than the 67.5 
h previously reported [13], which had motivated us choosing this 
variant, yet the published value is not even well supported by the pub-
lished data points shown in Figure 6A in [13] (see Discussion). The C- 
terminal DARPin fusion, HSA7-Ec1, showed a similar half-life as HSA7. 
This demonstrates the potential of HSA7 to substantially increase the 
short half-life of a DARPin from a few minutes [18,19] to more than one 
day and shows that the elimination kinetics are determined by HSA7. 
The determined half-lives of HSA7 and HSA7-Ec1 were thus com-
parable to those of MSA in its natural environment, in the blood circu-
lation of wt mice [11]. This is well consistent with the similar low 
micromolar affinity of these proteins to the murine FcRn. In contrast, 
HSA, which does not bind to the murine receptor, revealed a signifi-
cantly shorter half-life of 21 h. These data match and complement well 
the half-life values and murine FcRn binding parameters of HSAK573P, 
another high-affinity FcRn-binding variant of HSA [14]. 
Table 2 further shows that the investigated proteins have high 
apparent distribution volumes in the range of the calculated total body 
fluid of mice [34], which can be expected from the high extravasation 
and tissue penetration capacity of HSA. 
All observed AUC values are comparable between the investigated 
proteins, because the major part of the AUC value for serum albumins is 
influenced by the alpha distribution phase. Because the FcRn is highly 
saturated in vivo, recycling does not play a significant role in this phase 
and, consequently, all proteins examined are similarly distributed. 
4. Discussion 
We wished to investigate whether high-affinity variants of HSA can 
extend the half-life of binding proteins such as DARPins in wt mice, in 
order to have a greater freedom in the subsequent use of different dis-
ease models. For this reason, we developed first a highly efficient 
method of producing such fusion proteins in P. pastoris, and then 
established to what extent such high-affinity variants do increase the 
half-life and how this is correlated to the affinity to murine and human 
FcRn, compared to MSA and wt HSA. 
4.1. Optimization of the Pichia expression system 
To produce HSA, HSA7 and the DARPin-HSA7 fusion proteins at high 
quality and quantity, we established a facile production process for the 
high-yield protein expression in P. pastoris in a 0.5 L volume scale in 
shake flasks with titers of 300 mL/L, without the need for specific 
equipment. Using the designed vectors, we demonstrate that any DAR-
Pin can be readily fused to HSA or HSA7 and is secreted to the culture 
medium. 
While the protease-deficient strain SMD1163 is frequently used for 
production of secreted proteins [23], the strain KM71H, which is not 
protease-deficient, increased the yield 5 to 10-fold over SMD1163. We 
conclude that the yield-limiting process is not the degradation of serum 
albumin in the cell culture supernatant by yeast proteases (e.g., released 
by disintegrated cells), but the decreased fitness of the protease-deficient 
Table 1 









HSA7 human 13.3; 13.4 0.95; 0.87 72; 65 
HSA7-Ec1 human 33.3; 34.0 0.5; 0.5 15.2; 14.5 
MSA human 6.5; 7.8 3.7; 3.6 5700; 4600 
HSA7 murine 13.6; 15.1 56.5; 60.3 4200; 4000 
HSA7-Ec1 murine 39.0; 44.2 14.6; 14.5 374; 330 
MSA murine 1.5, 0.6; 1.5, 
1.1 
0.9, 22.4; 1.0, 
26.7 
599, 39990; 661, 
24000 
ka, association rate constant; kd, dissociation rate constant; KD equilibrium 
dissociation constant. Binding to MSA is shown for comparison. Plain text: high- 
density channel values, italics: low-density channel values. Note that a hetero-
geneous ligand model was fit to the MSA/mFcRn data, implicating two sets of 
parameters for each density. HSA does not bind to the murine FcRn (Figure S2), 
and numerous studies showed an approximately single-digit micromolar affinity 
to the human FcRn [13–16,44,52]. 
Fig. 3. Blood clearance of HSA, HSA7 and its fusion to the DARPin Ec1 in mice. 
All proteins were injected i.v. into mice at 4 mg/kg (N = 5 mice per group). 
Blood samples were collected 3 min, 1, 8, 24, 48, 72 and 96 h after injection. 
The serum concentrations were quantified by sandwich ELISA and interpolation 
with an appropriate protein standard. Data points are the average ± SD of N =
4–5 mice. A two-compartment model (bi-exponential decay) was fit to the data 
using GraphPad Prism version 6.07. 
Table 2 
Pharmacokinetic parameters of HSA, HSA7 and HSA7-Ec1 in mice.  
Construct τβ1/2 (h) AUC (h µg ml¡1) CL (ml h¡1) ke (h¡1) Vd (ml) 
HSA 21  283.9  0.409  0.033  12.4 
HSA7 29  422.9  0.246  0.024  10.3 
HSA7-Ec1 28  274.1  0.379  0.025  15.1 
The values were calculated from the blood clearance curves shown in Fig. 3. τβ1/ 
2: terminal serum elimination half-life; AUC: area under the curve; CL: clearance 
rate; ke: elimination rate constant; Vd: apparent volume of distribution. For 
comparison, the half-life of MSA was determined to be 30–35 h [11] 
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cells. PEP4, one of the deleted genes in SMD1163, encodes an aspartyl 
protease and such enzymes are involved in the vacuolar disposal of 
cellular debris arising from reactive oxygen species of the methanol 
metabolization pathway [35]. The other silenced gene, PRB1, also codes 
for a vacuolar protease (vacuolar proteinase B, [23]) and, hence, might 
play a similar role in this process. Consequently, we hypothesize that the 
protease-deficient strain SMD1163 is unable to process the high 
amounts of intracellular debris, which may be particularly abundant in 
high-density expression cultures protocols with high methanol 
concentrations. 
To rule out other reasons for the higher yield from strain KM71H, we 
also determined the gene copy number in selected clones by qPCR. We 
found no increased copy number over SMD1163 (Table S1) and, hence, 
concluded that the above discussed strain-fitness was mainly influencing 
protein expression. In addition, different leader sequences (e.g., HSA 
leader) were tested, but no significant influence on the protein titer or 
quality was detected (data not shown). 
Another component significantly increasing the protein yield was the 
elevated methanol concentration in our protocol, compared to 
commonly recommended procedures using the alcohol oxidase (AOX) 
promotor [24–26]. It has often been stated that methanol and its 
metabolic products are toxic to the Pichia cells [31], and this statement is 
often repeated by numerous online protocols from suppliers, yet without 
mentioning a tangible toxicity level, but instead recommending very low 
methanol levels of 0.5–2.0% (v/v). Thus, in standard protocols, meth-
anol is added only once at the very beginning of the cultivation, sup-
posedly providing sufficient levels for both growth and recombinant 
protein production with the AOX promotors. However, the cells are well 
protected from the reactive oxygen species products of the methanol 
metabolites H2O2 and formaldehyde [36]. These protection mechanisms 
include, amongst others, the oxidation of essential thiol groups in the 
AOX enzyme by H2O2 if this toxic substance is present in high amounts 
and cannot be neutralized by other protective pathways [26]. This thiol 
oxidation inactivates the AOX enzyme and thus methanol utilization 
ceases and, as a consequence, H2O2 production also stops, which would 
have resulted in reduced growth rates. Nevertheless, apoptosis or un-
controlled cell death are avoided by this protective mechanism. 
Consequently, until decreased growth-rates are detected, we found that 
methanol feeding can be increased for every lab-scale cultivation 
experiment. 
Furthermore, we used sorbitol as additional carbon source which, in 
contrast to glucose or glycerol [37–39], is not repressing the AOX pro-
motor [40]. While sorbitol has been applied in fermenter-scale cultiva-
tion experiments [41,42], we provide here for the first time a protocol 
for shake flask cultures. 
The yeast-expressed proteins showed a good quality, except for the 
N-terminal DARPin fusion of HSA7, Ec1-HSA7, which revealed an 
increased aggregate content (Fig. 1) and major deviations in analytical 
SEC from the calculated mass (data not shown). We hypothesize that the 
extremely fast and stable folding of the DARPin [17] might overstrain 
the export and folding control apparatus of the yeast cells, an effect 
which was previously observed in bacteria [43], and that this occurs 
already during expression, as all proteins were found to be stable 
4.2. Relation of half-life and binding to murine FcRn 
HSA7 is characterized by a strongly increased affinity to the human 
FcRn compared to HSA [13]. Whereas HSA does not effectively bind to 
the murine FcRn, the affinity of HSA7 to it had not been investigated yet, 
and it seemed plausible that HSA7 not only binds better to human FcRn 
but also to murine FcRn. Therefore, fusions to HSA7 might be a better 
model of half-life extension in wt mice than fusions to HSA, which does 
not undergo FcRn-dependent recycling in mice, for disease models 
where hFcRn transgenic mice cannot be used. Moreover, fusions to 
HSA7 might be moved to the clinic in a more straightforward way than 
fusions to MSA. We determined the affinity of HSA7 to murine FcRn to 
be in the micromolar range, and in mice its half-life was shown in the 
presented study to be 29 h, compared to only 21 h for HSA. Thus, HSA7 
equals the half-life of MSA in mice [11]. The presented study completes 
the picture of data collected with MSA [11] and HSAK573P [14]. Because 
all these proteins bind to the murine FcRn with a micromolar affinity, 
they consequently all show a half-life around 30 h in mice. Interestingly, 
the half-life-engineered HSA variants reach this value, even though they 
compete with an enormous excess of circulating MSA in the blood 
stream. Importantly, the exceedingly long half-life of HSA7 previously 
reported [13] could not be confirmed, and the published data points (cf. 
Figure 6A in [13]) would actually be more consistent with the rates 
determined here and for HSAK573P [14], as well as those for MSA itself 
[11]. Consequently, the provided more complete picture of the rela-
tionship between half-life and FcRn binding should be taken into ac-
count in preclinical drug testing, specifically because FcRn-mediated 
transport affects the biodistribution of the HSA-fused drug. 
Other receptors which may affect the tissue distribution and half-life 
of HSA variants in vivo include binding to albondin (gp60), SPARC, 
gp18, gp30 and the megalin-cubulin complex [3]. These interactions 
may also deplete the pool of circulating HSA, e.g., by receptor-mediated 
clearance. However, in contrast to FcRn binding, the effect of these in-
teractions can be considered equal for both HSA variants. Our wt mouse 
model to investigate the pharmacokinetic properties of HSA-fusion 
proteins may have some limitations such as the obvious cross-species 
difference in FcRn binding [14–16,44,45]. On the other hand, we are 
not limited to hFcRn transgenic strains, which cannot be used in all 
disease models. 
4.3. Comparison of non-recycling HSA fusions to other half-life extension 
strategies 
We previously compared the pharmacokinetic properties of DARPins 
fused to unstructured polypeptides and found a linear relationship be-
tween the apparent molecular weight and the blood residence time [20]. 
If the 21 h half-life of HSA in mice were included in the same data plot, it 
would deviate from the linear fit and the apparent size would appear 
much larger than its actual size of approximately 65 kDa, despite the fact 
that it is not bound by the murine FcRn, and would thus not be assumed 
to participate in endosomal recycling, Moreover, the same half-life 
around 20 h was also reported for MSA and IgGs in mice that do not 
express a functional FcRn [11]. 
In contrast, unstructured polypeptides fused to a DARPin, which 
show an apparent molecular weight around 300 kDa on gel filtration 
columns, and hence by far exceed the nominal renal filtration threshold, 
resulted in half-lives of only around 6 h [20]. Only with an apparent MW 
of 800–900 kDa, the value of 20 h could be reached [20]. This 
discrepancy between non-FcRn binding serum albumin variants and 
unstructured polypeptides suggests that the unstructured polypeptides 
(and by analogy, other unstructured polymers, such as PEG) are not as 
strictly excluded by the glomerular filter, but only retarded according to 
size. An exclusion is possible, but it requires a much higher apparent MW 
of about 800–900 kDa. 
Non-FcRn binding serum albumin variants show half-lives of 20 h in 
mice, which is significantly longer than those of other proteins of 
comparable size like antibody fragments [46], single-chain diabody 
constructs [47,48] or transferrin fusions [49]. These molecules display 
blood circulation half-lives between one to three hours. Consequently, 
the in vivo binding of serum albumin and IgGs to other receptors such as 
SPARC, gp60, Fcγ-receptors and the megalin-cubulin complex strongly 
affects tissue distribution and elimination kinetics [2], even in the 
absence of FcRn. Unexpectedly, in mice the role of the FcRn in half-life 
extension of serum albumin is relatively small, at most a factor 1.5, 
bringing the half-life from 20 h to 30 h. The tissue distribution mediated 
by other receptors, as well as the reabsorption in the kidney could also 
explain the herein determined high volumes of distribution, which are in 
the range of the total calculated body fluid of mice [34] for all tested 
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HSA constructs. In contrast, the distribution volumes of the recently 
reported DARPin-polypeptide fusions, which are not bound by specific 
receptors, are in the range of the total blood volume [20]. The high 
distribution volume of serum albumin in body tissues serves as a 
reservoir and, thus, results in comparably long blood circulation half- 
lives. It would, therefore, be interesting to explore the role of these 
other serum albumin binding receptors further, both with regard to their 
influence on half-life, as well as species differences. 
4.4. Binding kinetics of different serum albumin variants to human and 
murine FcRn 
To explain the increased half-life of HSA7 in mice when compared to 
HSA, we measured the affinities for the human and murine FcRn by 
detailed SPR analyses. Very notable were the low on-rates of 1.1 to 44.2 
× 103 M− 1s− 1 of all variants, while typical association rates of pro-
tein–protein interactions are in the range of 105–106 M− 1s− 1 [50]. These 
low association rates were also described by others [13–16,19,51]. 
Schmidt et al. [13] proposed a mechanism containing multiple re- 
structuring and binding events, e.g., the movement of an α-helix in 
DIIIB in HSA13 after initial binding, followed by W53 insertion into its 
binding pocket. Such a stepwise binding with slow rate-limiting steps 
could explain the observed slow on-rates, although we have no direct 
evidence for this mechanism. 
HSA7 shows a clearly lower affinity to the murine FcRn than to the 
human FcRn, and this is visible in the off-rate (Table 1). This difference 
in affinity between human and murine FcRn is similar to the difference 
found for another version of HSA with high affinity for the human re-
ceptor, HSAK573P [14]. Interestingly, the increased FcRn-affinity of the 
two published HSA variants, and consequently also the introduced 
murine FcRn binding and extended half-life in mice, cannot easily be 
explained from the crystal structures with the human FcRn. One might 
thus speculate that the introduced amino acid changes rather facilitate 
the reorientation of DIII and thus act indirectly or mediate long-range 
effects [14]. It is noteworthy that two different high-affinity versions 
of HSA (HSA7 and HSAK573P), carrying different amino acid sub-
stitutions, bind the murine receptor with a significantly lower affinity 
than the human one. At the same time, binding of MSA to the murine 
FcRn can only be described with a different binding model (as exem-
plified by its requirement for a two-component model (Table 2), corre-
lating with multiple differences in the interacting amino acids between 
the murine and human FcRn heavy chain homologs [13]. 
Altogether, this supports the recent finding that serum albumin do-
mains from different species (e.g., DIII from mice or humans) might play 
very different roles in the interaction with FcRn, again depending on the 
species of the receptor [16]. Interestingly, murine FcRn-bound HSA7 
shows an off-rate comparable to the fast-dissociating murine FcRn/MSA 
species from the heterogeneous analyte model. MSA binding to murine 
FcRn, however, displays another slow off-rate. A solved structure of the 
murine FcRn/MSA complex would be of interest to further elucidate the 
different binding modes and to explore whether an MSA or HSA deriv-
ative with high affinity for murine FcRn, e.g., obtained by in vitro evo-
lution, might extend the half-life in mice. 
Finally, taking our determined equilibrium dissociation constants 
together with additional published data [13,14,16], we conclude that 
low micromolar KD values are required for FcRn-recycling of serum al-
bumins. This minimal binding is necessary to increase the half-life from 
20 to 30 h in mice, and this is the value that MSA has evolved to in mice. 
Our careful measurements do not confirm the previously reported longer 
half-life of HSA7 of 67.5 h [13] (Table 2). If this long half-life were 
correct, we would also have expected a high murine FcRn-affinity of this 
protein, which we did not observe (Table 1). However, in mice trans-
genic for the human FcRn, the authors reported a half-life increase of 
only 1.5 fold from HSA to HSA7, which seems more plausible and better 
matches with our own data and those reported for another high affinity 
variant, HSAK573P [14]. 
4.5. Conclusions 
Our data suggest that, since HSA does not bind to the murine FcRn 
and hence does not reflect the true recycling and biodistribution 
mechanism of serum albumin in mice, only HSA variants engineered to 
bind to the murine receptor should be used to investigate the potential 
for half-life extension, and to improve the pharmacokinetics and efficacy 
of therapeutic agents under clinically relevant conditions. While one 
may argue that MSA might be used for such investigations, the use of an 
HSA variant would allow such a construct to more readily be moved into 
the clinic. 
In conclusion, we designed a novel platform for the fusion, highly 
efficient production in P. pastoris, and preclinical assessment of DARPin- 
serum albumin constructs in wt mice. Due to its very large distribution 
volume in different tissues like the lymphatic system and presumably 
improved tumor penetration, this platform also allows the design of 
DARPin-agents for novel applications in the future. The strategy can 
undoubtedly be transferred to other serum albumin fusions of well- 
behaved proteins. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Acknowledgements 
The authors would like to thank Valentina Kalichuk, Katja Zerjavic 
and Ronnie Steiger for their participation in optimizing the serum al-
bumin expression in P. pastoris and the purification of the proteins. We 
would like to thank the Functional Genomics Center Zurich, especially 
Peter Hunziker, for the N-terminal Edman analysis of different leader 
sequences and their advice in data interpretation. Furthermore, we 
would like to thank Simon Jurt (NMR Service, University of Zurich) and 
Christina Ewald (Cytometry facility, University of Zurich) for their help 
with NMR data collection and evaluation. This work was supported by 
Schweizerischer Nationalfonds grant number 31003A-170134 (to U. Z. 
W.) and 310030_192689 (to A.P.). J.T.A. and J.N. were supported by the 
Research Council of Norway (Grant no. 314909, 287927 and 274993) 
and South-Eastern Norway Regional Health Authority (Grant no. 
2021069). 
Appendix A. Supplementary material 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ejpb.2021.07.011. 
References 
[1] W.R. Strohl, Fusion proteins for half-life extension of biologics as a strategy to 
make biobetters, Biodrugs 29 (2015) 215–239. 
[2] M. Pyzik, K.M.K. Sand, J.J. Hubbard, J.T. Andersen, I. Sandlie, R.S. Blumberg, The 
neonatal Fc receptor (FcRn): a misnomer? Front. Immunol. 10 (2019) 1540. 
[3] M. Bern, K.M.K. Sand, J. Nilsen, I. Sandlie, J.T. Andersen, The role of albumin 
receptors in regulation of albumin homeostasis: Implications for drug delivery, 
J. Control. Release 211 (2015) 144–162. 
[4] F.E. Johansen, M. Pekna, I.N. Norderhaug, B. Haneberg, M.A. Hietala, P. Krajci, 
C. Betsholtz, P. Brandtzaeg, Absence of epithelial immunoglobulin A transport, 
with increased mucosal leakiness, in polymeric immunoglobulin receptor/ 
secretory component-deficient mice, J. Exp. Med. 190 (1999) 915–922. 
[5] R. Kitz, P. Ahrens, S. Zielen, Immunoglobulin levels in bronchoalveolar lavage fluid 
of children with chronic chest disease, Pediatr. Pulmonol. 29 (2000) 443–451. 
[6] M. Dockal, D.C. Carter, F. Rüker, The three recombinant domains of human serum 
albumin. Structural characterization and ligand binding properties, J. Biol. Chem. 
274 (1999) 29303–29310. 
[7] E.N. Hoogenboezem, C.L. Duvall, Harnessing albumin as a carrier for cancer 
therapies, Adv. Drug Deliv. Rev. 130 (2018) 73–89. 
[8] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in 
cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and 
the antitumor agent SMANCS, Cancer Res. 46 (1986) 6387–6392. 
H. Merten et al.                                                                                                                                                                                                                                 
European Journal of Pharmaceutics and Biopharmaceutics 167 (2021) 104–113
113
[9] J.T. Isaacs, S.L. Dalrymple, D.M. Rosen, H. Hammers, A. Olsson, T. Leanderson, 
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating 
increased uptake in the tumor microenvironment, Oncotarget 5 (2014) 8093–8106. 
[10] A. Wunder, U. Müller-Ladner, E.H.K. Stelzer, J. Funk, E. Neumann, G. Stehle, 
T. Pap, H. Sinn, S. Gay, C. Fiehn, Albumin-based drug delivery as novel therapeutic 
approach for rheumatoid arthritis, J. Immunol. 170 (2003) 4793–4801. 
[11] C. Chaudhury, S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Pearl, D.C. Roopenian, 
C.L. Anderson, The major histocompatibility complex-related Fc receptor for IgG 
(FcRn) binds albumin and prolongs its lifespan, J. Exp. Med. 197 (2003) 315–322. 
[12] V. Oganesyan, M.M. Damschroder, K.E. Cook, Q. Li, C. Gao, H. Wu, W. 
F. Dall’Acqua, Structural insights into neonatal Fc receptor-based recycling 
mechanisms, J. Biol. Chem. 289 (2014) 7812–7824. 
[13] M. Schmidt, S. Townson, A. Andreucci, B. King, E. Schirmer, A. Murillo, 
C. Dombrowski, A. Tisdale, P. Lowden, A. Masci, J. Kovalchin, D. Erbe, K. 
D. Wittrup, E. Furfine, T. Barnes, Crystal structure of an HSA/FcRn complex reveals 
recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic 
interface, Structure 21 (2013) 1966–1978. 
[14] J.T. Andersen, B. Dalhus, D. Viuff, B.T. Ravn, K.S. Gunnarsen, A. Plumridge, 
K. Bunting, F. Antunes, R. Williamson, S. Athwal, E. Allan, L. Evans, M. Bjørås, 
S. Kjaerulff, D. Sleep, I. Sandlie, J. Cameron, Extending serum half-life of albumin 
by engineering FcRn binding, J. Biol. Chem. 289 (2014) 13492–13502. 
[15] J.T. Andersen, M.B Daba, G. Berntzen, T.E. Michaelsen, I. Sandlie, Cross-species 
binding analyses of mouse and human neonatal Fc receptor show dramatic 
differences in immunoglobulin G and albumin binding, J. Biol. Chem. 285 (2010) 
4826–4836. 
[16] J. Nilsen, M. Bern, K.M.K. Sand, A. Grevys, B. Dalhus, I. Sandlie, J.T. Andersen, 
Human and mouse albumin bind their respective neonatal Fc receptors differently, 
Sci. Rep. 8 (2018) 14648. 
[17] A. Plückthun, Designed ankyrin repeat proteins (DARPins): binding proteins for 
research, diagnostics, and therapy, Annu. Rev. Pharmacol. Toxicol. 55 (2015) 
489–511. 
[18] C. Zahnd, M. Kawe, M.T. Stumpp, C. de Pasquale, R. Tamaskovic, G. Nagy- 
Davidescu, B. Dreier, R. Schibli, H.K. Binz, R. Waibel, A. Plückthun, Efficient tumor 
targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and 
molecular size, Cancer Res. 70 (2010) 1595–1605. 
[19] M. Simon, R. Frey, U. Zangemeister-Wittke, A. Plückthun, Orthogonal assembly of 
a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum 
albumin module for half-life extension, Bioconjug. Chem. 24 (2013) 1955–1966. 
[20] F. Brandl, H. Merten, M. Zimmermann, M. Béhé, U. Zangemeister-Wittke, 
A. Plückthun, Influence of size and charge of unstructured polypeptides on 
pharmacokinetics and biodistribution of targeted fusion proteins, J. Control. 
Release 307 (2019) 379–392. 
[21] S.B. Petkova, S. Akilesh, T.J. Sproule, G.J. Christianson, H. Al Khabbaz, A. 
C. Brown, L.G. Presta, Y.G. Meng, D.C. Roopenian, Enhanced half-life of genetically 
engineered human IgG1 antibodies in a humanized FcRn mouse model: potential 
application in humorally mediated autoimmune disease, Int. Immunol. 18 (2006) 
1759–1769. 
[22] J.M. Cregg, J.L. Cereghino, J. Shi, D.R. Higgins, Recombinant protein expression in 
Pichia pastoris, Mol. Biotechnol. 16 (2000) 23–52. 
[23] M. Ahmad, M. Hirz, H. Pichler, H. Schwab, Protein expression in Pichia pastoris: 
recent achievements and perspectives for heterologous protein production, Appl. 
Microbiol. Biotechnol. 98 (2014) 5301–5317. 
[24] J.M. Cregg, Introduction: distinctions between Pichia pastoris and other expression 
systems, Methods Mol. Biol. 389 (2007) 1–10. 
[25] J.M. Cregg, K.R. Madden, K.J. Barringer, G.P. Thill, C.A. Stillman, Functional 
characterization of the two alcohol oxidase genes from the yeast Pichia pastoris, 
Mol. Cell. Biol. 9 (1989) 1316–1323. 
[26] R. Couderc, J. Baratti, Oxidation of methanol by the yeast, Pichia pastoris. 
Purification and properties of the alcohol oxidase, Agric. Biol. Chem. 44 (1980) 
2279–2289. 
[27] N. Stefan, P. Martin-Killias, S. Wyss-Stoeckle, A. Honegger, U. Zangemeister- 
Wittke, A. Plückthun, DARPins recognizing the tumor-associated antigen EpCAM 
selected by phage and ribosome display and engineered for multivalency, J. Mol. 
Biol. 413 (2011) 826–843. 
[28] J.V. Schaefer, A. Plückthun, Engineering aggregation resistance in IgG by two 
independent mechanisms: lessons from comparison of Pichia pastoris and 
mammalian cell expression, J. Mol. Biol. 417 (2012) 309–335. 
[29] J.T. Andersen, S. Justesen, B. Fleckenstein, T.E. Michaelsen, G. Berntzen, V. 
E. Kenanova, M.B. Daba, V. Lauvrak, S. Buus, I. Sandlie, Ligand binding and 
antigenic properties of a human neonatal Fc receptor with mutation of two 
unpaired cysteine residues, FEBS J. 275 (2008) 4097–4110. 
[30] G. Berntzen, E. Lunde, M. Flobakk, J.T. Andersen, V. Lauvrak, I. Sandlie, Prolonged 
and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein 
by transiently transfected adherent 293E cells, J. Immunol. Methods 298 (2005) 
93–104. 
[31] W. Shen, Y. Xue, Y. Liu, C. Kong, X. Wang, M. Huang, M. Cai, X. Zhou, Y. Zhang, 
M. Zhou, A novel methanol-free Pichia pastoris system for recombinant protein 
expression, Microb. Cell Fact. 15 (2016) 178. 
[32] R.L. Rich, D.G. Myszka, Commercial optical biosensor literature, J. Mol. Recognit. 
18 (2005) 1–39. 
[33] R.L. Rich, D.G. Myszka, Grading the commercial optical biosensor literature-Class 
of 2008: ‘The Mighty Binders’, J. Mol. Recognit. 23 (2010) 1–64. 
[34] M.E. Chapman, L. Hu, C.F. Plato, D.E. Kohan, Bioimpedance spectroscopy for the 
estimation of body fluid volumes in mice, Am. J. Physiol. Renal Physiol. 299 
(2010) 280–283. 
[35] A.L. Vanz, H. Lunsdorf, A. Adnan, M. Nimtz, C. Gurramkonda, N. Khanna, U. Rinas, 
Physiological response of Pichia pastoris GS115 to methanol-induced high level 
production of the Hepatitis B surface antigen: catabolic adaptation, stress 
responses, and autophagic processes, Microb. Cell Fact. 11 (2012) 103. 
[36] F.S. Hartner, A. Glieder, Regulation of methanol utilisation pathway genes in 
yeasts, Microb. Cell Fact. 5 (2006) 39. 
[37] S. Hellwig, F. Emde, N.P. Raven, M. Henke, P. van Der Logt, R. Fischer, Analysis of 
single-chain antibody production in Pichia pastoris using on-line methanol control 
in fed-batch and mixed-feed fermentations, Biotechnol. Bioeng. 74 (2001) 
344–352. 
[38] P. Zhang, W. Zhang, X. Zhou, P. Bai, J.M. Cregg, Y. Zhang, Catabolite repression of 
Aox in Pichia pastoris is dependent on hexose transporter PpHxt1 and pexophagy, 
Appl. Environ. Microbiol. 76 (2010) 6108–6118. 
[39] S. Sommaruga, A. Lombardi, A. Salvadè, S. Mazzucchelli, F. Corsi, P. Galeffi, 
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